BiomX, Inc. Quarterly report pursuant to Section 13 or 15(d)

Shareholders Equity (Tables)

9 Months Ended

Sep. 30, 2020

	Nine months ended September 30,
	2020		2019

Underlying value of share of Common Stock ($)		5.59-6.21		2.03
Exercise price ($)		5.59-6.21		2.03
Expected volatility (%)		85.0		93.1
Term of the option (years)		6.25		6.25
Risk-free interest rate (%)		0.37-0.52		2.23

	For the nine months ended September 30, 2020
	Number of Options			Weighted average exercise price		Aggregate intrinsic value
				USD		USD in thousands
Outstanding at the beginning of period		3,143,802			1.09		25,733
Granted		893,700			6.16
Forfeited		(61,110	)		3.47
Exercised		(304,843	)		0.70
Outstanding at the end of period		3,671,549			3.08		12,665
Vested at end of period		1,738,957
Weighted average remaining contractual life – years as of September 30, 2020		7.82

Warrant

Issuance Date

Expiration Date

Exercise Price
Per Share (USD)

Number of
Shares of
Common Stock
Underlying
Warrants

Private Warrants issued to Yeda (see 1 below)

May 11, 2017

May 11, 2025

)

591,382

Private Warrants issued to founders (see 2 below)

November 27, 2017

10,589

Private Placement Warrants (see 3 below)

IPO
(December 13, 2018)

December 13, 2023

11.50

2,900,000

Public Warrants (see 4 below)

IPO
(December 13, 2018)

October 28, 2024

11.50

3,500,000

7,001,971

(*)	less than $0.001.

	Nine months ended September 30,
	2020		2019

Research and development expenses, net		1,345		520
General and administrative		783		360
		2,128		880

	Three months ended September 30,
	2020		2019

Research and development expenses, net		843		153
General and administrative		271		96
		1,114		249